About Isabl
Isabl is a Healthcare company based in New York (United States) founded in 2020 by Juan Medina, Andrew Kung, and Elli Papaemmanuil. Cancer patients genomes are analyzed by a medical diagnosis platform. Isabl has raised $3 million across 2 funding rounds from investors including HHS, Box 1 and Evolution VC Partners. The company has 3 employees. Its chief executive, as recorded, is Elli Papaemmanuil. Isabl offers products and services including Isabl GxT and WGTS SaaS. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Isabl Inc. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Isabl was founded in 2020 in New York, United States, within the healthcare technology sector. A platform for medical diagnosis is developed to examine genomes of cancer patients. The Isabl GxT platform is utilized to assess both genome and transcriptome data, enabling identification of mutations, disease monitoring, and biomarker detection. Operations focus on genomic analysis services for oncology applications.
- Total Equity Funding$3M (USD)
in 2 rounds
- Latest Funding Round$2.03M (USD), Grant
Apr 2023
- InvestorsHHS
& 6 more
- Employee Count3
Products & Services of Isabl
Isabl offers a comprehensive portfolio of products and services, including Isabl GxT and WGTS SaaS.
Analyzes entire tumor genome and transcriptome for cancer mutation detection
Platform for whole genome tumor sequencing services in cancer care
Funding Insights of Isabl
Isabl has successfully raised a total of $3M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $2.03 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 2
- Last Round Grant — $2.03M
- First Round $3M
(Jun 2022)
- Investors Count 7
All 2 funding rounds of Isabl with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | $2.03M | Grant | – | – | |
| Jun 2022 | $3M | Seed | – | – |
7 investors in total: 6 institutional and 1 angel.
Investors in Isabl
Isabl has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Box 1 and Evolution VC Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in tech startups are made by Evolution VC Partners. | evolutionvcp.com | New York, United States | ||
Angel funding is provided to Silicon Valley-based companies. | sandhillangels.com | Mountain View, United States | ||
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| box1.net | ||||
MA Milad Alucozai | Indian angel investor, advisor at Lightspeed India, focused on early-stage startups | unknown_eb489805bb6445099 |
Investor details for Isabl
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Isabl
5 people are tracked at Isabl (5 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Juan Medina | Co-Founder | Leadership |
Andrew Kung | Co-Founder | Leadership |
Elli Papaemmanuil | Co-Founder & CEO | Leadership |
Max Levine | Chief Bioinformatics Officer | Leadership |
Minal Patel | Vp, Business Operations | Leadership |
Complete people profiles for Isabl
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Isabl
3 dated milestones of Isabl across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Isabl is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Grant, of $2.0M.
Competitors of Isabl
Isabl has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Isabl
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Isabl (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Isabl
Isabl was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Isabl is headquartered in New York, United States. It is registered at New York, New York, United States.
Elli Papaemmanuil is the CEO of Isabl, as recorded in our data. They have also founded this company.
Isabl is a funded company, having raised a total of $3M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Jun 2022.
Isabl has 3 employees.
Isabl was founded in 2020 in New York, United States, within the healthcare technology sector. A platform for medical diagnosis is developed to examine genomes of cancer patients. The Isabl GxT platform is utilized to assess both genome and transcriptome data, enabling identification of mutations, disease monitoring, and biomarker detection. Operations focus on genomic analysis services for oncology applications.
Isabl's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Isabl offers Isabl GxT and WGTS SaaS.
Isabl has 7 investors. Key investors include HHS, Box 1, Evolution VC Partners, Milad Alucozai, and Sand Hill Angels.
Isabl operates through Isabl Inc..